KSH 01
Alternative Names: KSH-01; KSH01 injection; KSH01-TCRTLatest Information Update: 18 Oct 2022
At a glance
- Originator TCRx Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Solid tumours
Most Recent Events
- 14 Oct 2022 TCRx Therapeutics plans a phase I trial for Solid tumours (NCT05580796)
- 19 Aug 2022 Phase-0 for Solid tumours (Recurrent, Late-stage disease, Second-line therapy or greater) in China (Parenteral) (NCT05539833)